PLGA-Mediated Delivery of Redox Modulating Agents for Treatment of Chronic Obstructive Pulmonary Disorder (COPD)
Oxidative stress and chronic inflammation are important features in the pathogenesis of COPD. The increased oxidative stress in patients with COPD is the result of an increased burden of inhaled oxidants, as well as increased amounts of reactive oxygen species (ROS) generated by various inflammatory, immune and epithelial cells of the airways. Hence, targeting systemic and local oxidative stress with redox modulating agents like superoxide dismutase (SOD) and catalase can be expected to be useful in the treatment of COPD. Current antioxidant enzyme therapy for COPD lacks adequate specificity and efficacy, insufficient delivery which provides an impetus to develop targeted therapies to achieve greater efficacy with fewer side effects. Nanoparticle (NP) mediated drug delivery is gaining importance now-a-days because of highly specificity and selectivity. Hence, targeted delivery could be achieved by the nanoparticles conjugated redox modulating agents in the treatment of COPD. Poly lactic-co-glycolic Acid (PLGA) can be used for synthesis of polymeric PLGA nanoparticles having biodegradability, biocompatibility, FDA approval, defined formulations and adaptability to various types of drugs, better surface properties for interaction with biological materials, sustained release, less toxicity and target delivery to cells or organs. PLGA nanoparticles loaded with SOD/Catalase therefore is the preferred choice for drug delivery and treatment of COPD.
Keywords - Antioxidant; COPD; Polymeric Nanoparticles